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MATRIX METALLOPROTEINASE AND TISSUE INHIBITOR OF
METALLOPROTEINASE ACTIVITY IN SYNOVIAL FLUID FROM HORSES
WITH POST-TRAUMATIC OSTEOARTHRITIS
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Minnesota, St. Paul, MN, USA; zUniv. of Florida, Gainesville, FL, USA
Purpose: Matrix metalloproteinases (MMPs) are enzymes that are
responsible for degradation of the extracellular matrix of articular car-
tilage. Tissue inhibitors of metalloproteinases (TIMPs) are natural
inhibitors that bind 1:1 with MMPs blocking their actions. In general,
MMP activity has been shown to increase when cartilage damage is
present, whereas TIMP activity is variable. The objective of the current
study was to compare MMP and TIMP concentrations and their ratios in
synovial ﬂuid (SF) from horses with normal joints (controls) and those
with post-traumatic osteoarthritis (PTOA). Our hypothesis was that
MMP concentrations would be higher and TIMP concentrations would
be lower in joints with PTOA compared to controls, resulting in higher
MMP to TIMP ratios in injured horses. If so, this would account for less
regulation of MMP activity in injured joints, potentiating further
articular cartilage damage.
Methods: SF was taken from the metacarpophalangeal (n ¼ 11) and/or
carpal (n ¼ 10) joints from 19 horses (age range 2-14 years) that had
arthroscopic evidence of PTOA and from the metacarpophalangeal (n ¼
10) and/or carpal (n ¼ 4) joints from 12 control horses (age range 4-9
years) with radiographically and clinically normal joints. SF was asep-
tically collected by needle arthrocentesis without lavage, centrifuged,
and decanted. Commercially available multiplex assays (R&D Systems,
Minneapolis, MN) were used to measure MMP -1, -2, -3, -9, and -13
(Human MMP Magnetic Luminex Performance Assay) and TIMP -1, -2,
-3, and -4 (Human TIMP Magnetic Luminex Performance Assay 4-plex
kit) on a Luminex xMap technology based multiplex array system (Bio-
Plex 200 system, Bio-Rad Laboratories, Hercules, CA). SF was digested
with hyluronidase and then diluted at appropriate dilutions and were
run in duplicate (TIMPs) or triplicate (MMPs). MMP to TIMP ratios were
calculated for each group. Descriptive statistics were performed as well
as a Mann Whitney test to determine differences between PTOA horses
and controls. Spearman rank correlations were performed to determine
correlations between MMPs and TIMPs. P<0.05 was considered
signiﬁcant.
Results: Concentrations for MMP-2, MMP-3, and TIMP-2 were all sig-
niﬁcantly higher in SF from PTOA joints compared to control joints
(P<0.05). In addition, the MMP-2/TIMP-1, MMP-2/TIMP-4, and MMP-3/
TIMP-3 ratios were all signiﬁcantly higher in PTOA joints compared to
control joints (P<0.05). In PTOA joints, 9/17 (53%) samples had MMP-3
concentrations higher than 100 pg/mL compared to only 3/14 (21%) for
controls. In addition, in those PTOA horses in which MMP-3 concen-
trations were >100 pg/mL, 8/9 (89%) had MMP-1 concentrations >100
pg/mL, 7/9 (78%) had MMP-2 concentrations >0 pg/mL, 5/9 (56%) had
MMP-9 concentrations >100 pg/mL, and 3/9 (33%) had MMP-13 con-
centrations >0 pg/mL, whereas control horses with MMP-3 concen-
trations >100 pg/mL had no horses with MMP-1 concentrations >100
pg/mL, MMP-2 concentrations >0 pg/mL, MMP-9 concentrations >100
pg/mL, and MMP-13 concentrations >0 pg/mL. MMP-1 and MMP-3
were highly correlated (P<0.001; R ¼ 0.793) as was MMP-2 and TIMP-2
(P ¼ 0.002; R ¼ 0.716).
Conclusions: Post traumatic osteoarthritic joints have selectively
higher MMP and TIMP concentrations than control joints. In addition,
PTOA joints also have higher ratios of MMPs to TIMPs when examining
MMP-2 relative to TIMP-1 and -4, as well as MMP-3 relative to TIMP-3.
Most MMP concentrations were higher in PTOA joints than controls
while TIMP concentrations generally stayed the same or decreased
(except for TIMP-2). This indicates that when PTOA develops, TIMP
concentrations generally do not directly increase in response to
increased MMP concentrations. This could allow MMPs to further
degrade the extracellular matrix of articular cartilage. TIMP-2 was the
only TIMP to increase when PTOAwas present, which may be related to
its capability to drive the release and activation of MMP-2, as also
demonstrated by the correlation between MMP-2 and TIMP-2. In those
PTOA joints in which MMP-3 concentrations were >100 pg/mL, multi-
ple other MMP concentrations were elevated as well whereas no con-
trol samples followed this pattern. This demonstrates the likely
interplay between MMPs once PTOA develops where one MMP stim-
ulates the production and the activation of others to drive further car-
tilage degradation. SF analysis of MMPs and TIMPs as indirectbiomarkers of PTOA may prove to have value in monitoring the pro-
gression of OA, especially if combined with cytokines, chemokines, and
traditional biochemical biomarkers of OA.
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ASSOCIATION BETWEEN BIOCHEMICAL CARTILAGE MARKERS AND
CLINICAL SYMPTOMS IN PATIENTS WITH HIP OSTEOARTHRITIS:
COHORT STUDY WITH TWO-YEAR FOLLOW-UP
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Purpose: Biomarkers are deﬁned as characteristics that are objectively
measured and evaluated as an indicator of normal biological processes,
pathogenic processes, or pharmacologic responses to a therapeutic
intervention. The availability of biomarkers that can assist in diagnosing
early-stage OA, predicting OA progression, and assessing therapeutic
responses could improve early diagnosis and help monitor the effect of
OA treatment. The goal of this study was to assess the associations
between two urinary biomarkers (CTX-II and CIIM) and severity of hip
pain in patients with hip OA over a 2-year period, and establish whether
the level of these biomarkers at baseline could predict a speciﬁc course
of hip pain.
Methods: The study population consisted of primary care patients
diagnosed with hip OA (n ¼ 222) who participated in a prospective
randomized controlled trial that assessed the effect of glucosamine
sulfate (GOAL trial). Patients were eligible if they met one of the
American College of Rheumatology criteria for hip OA. Patients who had
undergone or were awaiting total hip replacement surgery and patients
with a Kellgren and Lawrence (KL) score of 4 were excluded. Patients
were also excluded if they had renal disease, liver disease, diabetes
mellitus, or were already taking glucosamine. The outcomes were level
of the biomarkers uCTX-II and uCIIM, and hip pain, measured with the
Western Ontario and McMasters University Osteoarthritis Index
(WOMAC) and with the Visual Analog Scale (VAS). All outcomes were
measured at baseline, and at 6, 12, 18, and 24 months follow-up.
Associations between level of and biomarkers and hip pain severity
were assessed using linear mixed-model analysis for repeated meas-
urements. Adjustments included: age, gender, body mass index, allo-
cated treatment, duration of hip complaints, type of OA and severity of
radiologic hip OA. A subgroup analysis was performed with patients
with minimal radiologic hip OA (KL<2) and patients with deﬁnite
radiologic hip OA (KL2). Using the 3-monthly repeated pain meas-
urements during 2-year follow-up, ﬁve distinct hip pain courses (tra-
jectories) were identiﬁed in the GOAL trial previously: mild pain,
moderate pain, high pain, regularly progressive pain, and highly pro-
gressive pain. These trajectories of hip pain were used as outcome to
investigate whether the level of biomarkers at baseline could predict
membership in one of the ﬁve trajectories using multinomial regression
analysis.
Results: The mean age of the 222 patients participating in the GOAL
trial was 63.4 (SD 9.0) years and 69.4% of patients were female. At
baseline, the meanWOMAC pain score was 34.2 (SD 23.1) and the mean
VAS pain scorewas 32.4 (SD 25.9). Themedian uCIIM pg/umol creat was
61.7 (IQR 51.5) and the median uCTX-II pg/umol creat was 332 (IQR
355).
At baseline, biomarkers for 197 (89%) patients were available for anal-
ysis, compared with 177 (80%) patients at 6-months follow-up, 190
(86%) at 12 months, 186 (84%) at 18 months and 187 (84%) patients at
24-months follow-up.
Patients in the highly progressive pain trajectory and the moderate pain
trajectory were more likely to have a higher loguCTX-II at baseline (OR
6.5; 95% CI 1.6-28.2 and OR 4.8; 95%CI 1.0-22.8, respectively) than
patients in the mild pain trajectory.
Neither loguCTX-II nor loguCIIM were cross-sectionally associated with
WOMAC pain or VAS pain during the 2-year follow-up. The subgroup
analysis of patients with deﬁnite radiographic OA (K&L2) at baseline
(n ¼ 108) showed a signiﬁcant association between loguCTX-II and VAS
pain (coefﬁcient 16.7; 95% CI 7.3-26.1). The cross-sectional association
between loguCTX-II andWOMAC painwas not signiﬁcant in the deﬁnite
radiographic OA group, nor were the associations between loguCIIM
and WOMAC pain or VAS pain. In the group with minimal radiographic
OA at baseline (n ¼ 114), no associations were found between loguCTX-
II, loguCIIM and the pain scores.
